Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.000
+0.044 (4.62%)
At close: Nov 20, 2024, 4:00 PM
1.030
+0.030 (3.00%)
After-hours: Nov 20, 2024, 7:44 PM EST
Lucid Diagnostics Employees
Lucid Diagnostics had 70 employees as of December 31, 2023. The number of employees decreased by 4 or -5.41% compared to the previous year.
Employees
70
Change (1Y)
-4
Growth (1Y)
-5.41%
Revenue / Employee
$59,843
Profits / Employee
-$747,343
Market Cap
53.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 70 | -4 | -5.41% |
| Dec 31, 2022 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BGM Group | 298 |
| Cytosorbents | 186 |
| Exagen | 179 |
| Prelude Therapeutics | 128 |
| Precision BioSciences | 109 |
| Aadi Bioscience | 89 |
| Affimed | 76 |
| Shattuck Labs | 75 |
LUCD News
- 1 day ago - Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PRNewsWire
- 3 days ago - Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 7 days ago - Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PRNewsWire
- 14 days ago - Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PRNewsWire
- 16 days ago - Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PRNewsWire
- 22 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - PRNewsWire
- 5 weeks ago - Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - PRNewsWire